In a Phase II clinical trial, researchers are using autologous (the patients’ own) mesenchymal stem cells to treat Alzheimer’s disease. According to the Centers for Disease Control (CDC) 5.7 million Americans are currently suffering from Alzheimer’s [with approximately 5.5 million over the age of 65 and approximately 220k under 65 experiencing early onset Alzheimer’s] with the number expected to triple by 2060. Additionally, the disease is one of the top 10 leading causes of death in U.S. adults; and while incidents of other common ailments like heart disease and cancer are decreasing, Alzheimer’s is on the rise.
The double-blind study utilizes a treatment called AstroStem, which isolates and expands the mesenchymal stem cells obtained from the patient. By personalizing the treatment and utilizing the patients’ own stem cells, the study minimizes any risk of rejection, since the immune system will recognize these cells as its own. The stem cell treatment will be administered to the patients over a 2-week interval, after which the patients will be observed in follow-ups at 30 weeks and 52 weeks post treatment. The trial is currently recruiting patients aged 50 and older with an Alzheimer’s diagnosis.
Advances in stem cell based regenerative treatments are creating more effective treatment options for patients suffering from a wide variety of disease, trauma and injury. To learn more about stem cells, and how families can bank their own valuable stem cells by recovering the very powerful dental pulp stem cells during routine dental procedures; such as wisdom teeth extractions or the during the loss of baby teeth, visit StemSave or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.